Clinical trial · Observational
Integrative Analysis of Large-cell Lung Cancer
Integrative Analysis of Large-cell Lung Carcinoma
NCT02917369CI-TRIAL-00024066LCLCrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Integrative analysis of LCLC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Normal lung tissue | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Normal lung tissue
- description
- Normal lung tissue from LCLC patients
- interventionNames
- Other: Normal lung tissue
- label
- LCLC tissues
- description
- LCLC tissues from LCLC patients
- interventionNames
- Other: Normal lung tissue
- label
- Metastasis tissues
- description
- Metastasis tissues from LCLC patients
- interventionNames
- Other: Normal lung tissue
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≤ 75 years with histologically proven LCLC * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy
References
Publications (1)
- RESULTTorre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID 25651787